Skip to content
OpenCapital
Get started

STERIS STE Healthcare Segment — R&D

Other segment segments

Life Sciences:
$2.8M+16.7%
AST
$800K-27.3%

Similar metrics at other companies

OSI Systems logo
OSISHealthcare Division — Research And Development Expense
$4.63M+7.7%
Baxter International logo
BAXHealthcare Systems & Technologies — Research and development expenses
$49M+8.9%
CareCloud, Inc. logo
CCLDHealthcare IT — Research And Development Expense
$2.42M+95.6%
Vaxcyte, Inc. logo
PCVXReportable Segment — R&D
$256.43M+147%
DuPont de Nemours, Inc. logo
DDHealthcare & Water Technologies — Research and development expenses
$22M+10.0%
Cronos Group logo
CRONReportable Segment — R&D
$1.41M+78.2%

Other financials

Income statement

See full
Revenue$1.6B+7.3%
Gross profit$697.2M+8.8%
Operating income$316.8M+46.6%
Net income$220.2M+51.2%
EPS (diluted)$2.24+52.4%

Balance sheet

See full
Cash & equivalents$439.6M+156%
Total debt$2.1B-10.3%
Total equity$7.2B+8.8%
Total assets$10.7B+5.8%

Cash flow

See full
Operating cash flow$335.4M+28.6%
CapEx$90.2M+27.2%
Free cash flow$245.2M+29.1%

Valuation

See full
Market cap$20.52B-9.4%
Enterprise value$22.17B-8.8%
P/E26.2×-8.8×
P/S3.5×-0.6×

Profitability

See full
Gross margin44.2%+0.2pp
Operating margin18.6%+2.7pp
Net margin13.2%+1.9pp
FCF margin16.4%+2.1pp

Returns & leverage

See full
Return on equity11.3%+1.8pp
Debt / equity0.3×-0.1×
Current ratio2.1×+0.1×

Where this comes from

Reported directly by STERIS in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: STERIS’s 10-K, filed May 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about STERIS's healthcare segment — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is STERIS's healthcare segment — R&D?
STERIS (STE) reported healthcare segment — R&D of $25.3M in Q1 2026.
How has STERIS's healthcare segment — R&D changed year-over-year?
STERIS's healthcare segment — R&D increased by 6.8% year-over-year, from $23.7M to $25.3M.
What is the long-term trend for STERIS's healthcare segment — R&D?
Over 3 years (2023 to 2026), STERIS's healthcare segment — R&D has grown at a 4.8% compound annual growth rate (CAGR), from $84.68M to $97.5M.
What does healthcare segment — R&D mean?
This metric tracks the investment in innovation, product development, and clinical testing specifically for the healthcare segment's portfolio. It is a key indicator of the company's commitment to long-term growth through new product launches and technological advancements in sterilization and infection prevention.